Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Hide Transcript
But in such a new field of research, customers of these weight-loss startups are essentially test subjects, says Chastain: The danger to consumers is that they take on risk and expensive medication based on a claim that is not scientifically basedthats not evidence-based. Startups, by nature, exist to fix problems
Retatrutide is still in clinical development and has not been approved for UK use by the MHRA or any global regulator
UK patients with obesity should engage with existing NICE-recommended services, including licensed medicines such as orlistat or semaglutide 2.4 mg (Wegovy)
Well-capitalized public companies, VC-backed startups, regional operators - they all offer some version of the same model
US$ 25.71
US$ 27.45
US$ 21.40
US$ 22.96
US$ 23.79
